Estimations des analystes de Wall Street pour Nektar Therapeutics (NKTR): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 22 |
| Conserver | 6 |
| Vente | 5 |
| Vente forte | 0 |
| Analystes au total | 33 |
| Note moyenne (1-5) | 0.52 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-2.13 | ||
| 2026-08-13 | $-1.23 | $-1.97 | +37.6% |
| 2026-05-07 | $-1.82 | $-1.58 | -15.0% |
| 2026-03-12 | $-1.78 | $-2.47 | +28.1% |
| 2025-11-06 | $-1.85 | $-2.85 | +35.1% |
| 2025-08-07 | $-2.95 | $-3.03 | +2.6% |
| 2025-05-08 | $-3.60 | $-2.56 | -40.4% |
| 2025-03-12 | $0.45 | $-0.18 | +350.0% |
Ratios de valorisation
| Prix / Valeur comptable | 2.47 |
| EV / EBITDA | -15.61 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $165.4M | $307.7M | $1.19B | $114.6M | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M |
| Coût des Ventes | $30.2M | $30.5M | $24.4M | $21.4M | $19.5M | $24.9M | $21.6M | $36.6M | $30.7M | 0 |
| Marge Brute | $135.2M | $277.2M | $1.17B | $93.2M | $133.4M | $77.0M | $70.4M | $53.5M | $67.7M | $55.2M |
| R&D | $203.8M | $268.5M | $399.5M | $434.6M | $408.7M | $400.3M | $218.3M | $114.2M | $120.9M | $117.3M |
| Frais Généraux | $44.3M | $52.4M | $81.4M | $98.7M | $104.7M | $122.8M | $92.3M | $77.4M | $76.8M | $68.7M |
| Charges Opérationnelles | $248.1M | $320.8M | $481.0M | $533.3M | $513.4M | $523.1M | $310.7M | $190.9M | $172.9M | $186.0M |
| Résultat Opérationnel | -$112.9M | -$59.6M | $687.9M | -$440.0M | -$379.9M | -$446.1M | -$240.2M | -$137.4M | -$105.2M | -$130.8M |
| EBITDA | -$97.3M | -$42.5M | $734.3M | -$382.7M | -$394.3M | -$461.8M | -$323.9M | -$243.1M | -$86.7M | -$137.0M |
| Charges d'Intérêt | $42.2M | $41.0M | $42.8M | $46.4M | $37.1M | $47.3M | $28.9M | $25.3M | $28.1M | $26.2M |
| Résultat Avant Impôts | -$152.6M | -$96.1M | $682.7M | -$440.1M | -$443.9M | -$523.3M | -$365.0M | -$276.3M | -$119.2M | -$164.2M |
| Impôts | $876000 | $616000 | $1.4M | $613000 | $493000 | $557000 | $3.2M | -$200000 | -$239000 | -$138000 |
| Résultat Net | -$153.5M | -$96.7M | $681.3M | -$440.7M | -$444.4M | -$523.8M | -$368.2M | -$276.1M | -$119.0M | -$164.1M |
| BPA | $-16.50 | $-9.30 | $56.70 | $-37.80 | $-37.33 | $-42.90 | $-29.51 | $-21.79 | $-8.68 | $-9.73 |
| BPA Dilué | $-16.50 | $-9.30 | $56.70 | $-37.80 | $-37.33 | $-42.90 | $-29.51 | $-21.79 | $-8.68 | $-9.73 |
| Actions en Circulation (Diluées) | $9.3M | $10.4M | $12.0M | $11.7M | $11.9M | $12.2M | $12.5M | $12.7M | $13.7M | $16.9M |
Prix
| Prix | $67.38 |
| Capitalisation | $1.9B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: AMLX · ATAI · ELVN · IMTX · INBX · ORIC · RLAY
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de NKTR: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions